First Post-Approval Clinical Use of F-18 Flurpiridaz With Exercise Cardiac PET in the United States

Q4 Medicine

JACC. Case reports Pub Date : 2025-10-01 DOI:10.1016/j.jaccas.2025.105279

Suman Tandon MD , Omar K. Khalique MD , Lu Q. Chen MD

{"title":"First Post-Approval Clinical Use of F-18 Flurpiridaz With Exercise Cardiac PET in the United States","authors":"Suman Tandon MD , Omar K. Khalique MD , Lu Q. Chen MD","doi":"10.1016/j.jaccas.2025.105279","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>F-18 flurpiridaz is a novel radiotracer approved for positron emission tmography (PET) myocardial perfusion imaging. Its long half-life supports exercise stress testing, and its short positron range and high myocardial extraction fraction provide superior image resolution.</div></div><div><h3>Early Reports Summary</h3><div>A 70-year-old man with known coronary artery disease and prior coronary revascularization underwent exercise cardiac PET with F-18 flurpiridaz for chest discomfort. PET showed ischemia in the left anterior descending and right coronary artery territories. Coronary angiography revealed a severe mid-left anterior descending lesion and a severe proximal lesion in a small-caliber right posterior descending artery.</div></div><div><h3>Discussion</h3><div>Ischemia on PET correlated with coronary angiography and optical coherence tomography, guiding revascularization and altering clinical management.</div></div><div><h3>Novelty</h3><div>This case represents the first post-approval clinical experience of F-18 flurpiridaz with exercise cardiac PET imaging in the United States.</div></div><div><h3>Take-Home Message</h3><div>F-18 flurpiridaz has made exercise cardiac PET feasible in the clinical setting.</div></div>","PeriodicalId":14792,"journal":{"name":"JACC. Case reports","volume":"30 30","pages":"Article 105279"},"PeriodicalIF":0.0000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC. Case reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666084925020601","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background

F-18 flurpiridaz is a novel radiotracer approved for positron emission tmography (PET) myocardial perfusion imaging. Its long half-life supports exercise stress testing, and its short positron range and high myocardial extraction fraction provide superior image resolution.

Early Reports Summary

A 70-year-old man with known coronary artery disease and prior coronary revascularization underwent exercise cardiac PET with F-18 flurpiridaz for chest discomfort. PET showed ischemia in the left anterior descending and right coronary artery territories. Coronary angiography revealed a severe mid-left anterior descending lesion and a severe proximal lesion in a small-caliber right posterior descending artery.

Discussion

Ischemia on PET correlated with coronary angiography and optical coherence tomography, guiding revascularization and altering clinical management.

Novelty

This case represents the first post-approval clinical experience of F-18 flurpiridaz with exercise cardiac PET imaging in the United States.

Take-Home Message

F-18 flurpiridaz has made exercise cardiac PET feasible in the clinical setting.

查看原文本刊更多论文

在美国，F-18氟吡达与运动心脏PET的首次临床批准后使用

f -18氟吡达兹是一种新型的放射性示踪剂，被批准用于正电子发射断层显像（PET）心肌灌注成像。其长半衰期支持运动应激测试，其短正电子范围和高心肌提取率提供了优越的图像分辨率。早期报告总结：一名已知冠状动脉疾病和既往冠状动脉血运重建术的70岁男性，因胸部不适接受F-18氟吡达运动心脏PET治疗。PET显示左前降支和右冠状动脉区域缺血。冠状动脉造影显示严重的左中前降支病变和小口径右后降支近端病变。探讨PET缺血与冠状动脉造影和光学相干断层扫描的相关性，指导血管重建和改变临床处理。该病例代表了F-18氟吡达兹在美国首次批准后与运动心脏PET成像的临床经验。氟吡达兹使心脏PET运动在临床环境中变得可行。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊